|
2011, Volume 27, Number 3, Page(s) 204-209
|
|
DOI: 10.5146/tjpath.2011.01076 |
Vascular Endothelial Growth Factor Expression in Low and High Grade B-cell Non-Hodgkin's Lymphomas |
İrem Hicran ÖZBUDAK, Bahar AKKAYA, Gülten KARPUZOĞLU |
Department of Pathology, Akdeniz University, Faculty of Medicine, ANTALYA, TURKEY |
Keywords:
Vascular endothelial growth factor, B-cell non-Hodgkin's lymphoma |
Objective: Angiogenesis is critical for the development of tumors.
Although vascular endothelial growth factor is a well-known
proangiogenic factor, its impact on B-cell non-Hodgkin's lymphoma
is not clear. The aim of this study is to evaluate vascular endothelial
growth factor expression in subtypes of B-cell non-Hodgkin's
lymphoma.
Material and Method: Fifty-one patients with diagnoses of low and
high grade B-cell non-Hodgkin's lymphoma were randomly selected
and proper slides were immunostained with vascular endothelial
growth factor antibody. The percentage of positive cells was recorded
as the vascular endothelial growth factor score. A cut-off point was
determined by using the median vascular endothelial growth factor
score of all cases. The patients were subclassified as negative, weak or
strong positive according to this cut-off point.
Results: The study cohort included 26 women and 25 men, aged 5
to 82 years. The number of low-grade patients diagnosed as grade
I follicular lymphoma and small lymphocytic lymphoma were 7
and 6; while the number of high grade patients diagnosed as diffuse
large B-cell lymphoma and Burkitt's lymphoma were 29 and 9,
respectively. Twenty-five patients (49.0%) showed strong and 10
patients (19.6%) showed weak vascular endothelial growth factor
immunoreactivity, while 16 patients (31.4%) showed no staining. No
statistically significant difference was found for vascular endothelial
growth factor expression between subtypes of B-cell non-Hodgkin's
lymphoma; as well as between low and high grade groups.
Conclusion: Further studies in large and specific series are needed
to determine the role of vascular endothelial growth factor receptor
related pathways in the development and progression of B-cell
non-Hodgkin's lymphomas.
|
|
|
|